Excellent
Mostly Aligned
Patient Risk:
Low
Summary
The AI-generated fetal toxicity claim is fully supported by MICARDIS labeling sections 5.1 (Fetal Toxicity) and 8.1 (Pregnancy), including increased fetal/neonatal morbidity and death and discontinuation when pregnancy is detected.
Category Scores
Accurate Statements
MICARDIS carries fetal toxicity risk in pregnancy (especially 2nd/3rd trimester), including reduced fetal renal function and increased fetal/neonatal morbidity and death; discontinue as soon as pregnancy is detected.
Supported by 5.1 Fetal Toxicity and reinforced by 8.1 Pregnancy: RAS drugs in 2nd/3rd trimester reduce fetal renal function and increase fetal/neonatal morbidity and death; discontinue MICARDIS as soon as pregnancy is detected.
Unsupported Statements
Contradictions
Important Omissions
The AI claim does not mention additional labeling details of fetal toxicity outcomes (e.g., oligohydramnios, fetal lung hypoplasia, skeletal deformities such as skull hypoplasia, and infant monitoring/management such as serial ultrasound and neonatal monitoring for hypotension/oliguria/hyperkalemia).
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Low
The evaluated statement is a label-supported fetal safety warning and includes the key action to discontinue upon detection of pregnancy; omitted items are additional specifics rather than contradictory or misleading guidance.
Regulatory Assessment
| On Label |
Yes |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Low |
Recommendation
Mostly Aligned
Primary Issue
Omission of several label-specific details (e.g., oligohydramnios-associated outcomes and infant monitoring/management) within the cited sections.
Suggested Improvement
Include the additional label-specified fetal/neonatal outcomes and monitoring/discontinuation nuances from 5.1 and 8.1 when summarizing fetal toxicity.